GLPwatch
Papers (12034)
Page 98 of 201, ranked by citation count.
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
- A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
- Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.
- Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice.
- Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study.
- Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?
- The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.
- Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin.
- Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.
- Use of exenatide and liraglutide in Denmark: a drug utilization study.
- Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
- Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
- Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis.
- Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
- Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
- Lixisenatide as add-on therapy to basal insulin.
- Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide.
- A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.
- Semaglutide-associated hyposalivation: A report of case series.
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.
- A Specific HPLC Method to Determine Residual HEPES in [<sup>68</sup>Ga]Ga-Radiopharmaceuticals: Development and Validation.
- Targeting microglial GLP1R in epilepsy: A novel approach to modulate neuroinflammation and neuronal apoptosis.
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.
- Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.
- Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.
- [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
- Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
- Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
- Exendin-4 decreases ghrelin levels through mTOR signaling.
- The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.
- NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.
- Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
- Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
- Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
- Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.
- The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells.
- Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
- High price and demand for semaglutide means lack of access for US patients.
- Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.
- [Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats].
- Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.
- GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.
- Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.
- Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
- GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.
- Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
- A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.
- Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes.
- GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation.
- Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
- <sup>68</sup>Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.
- Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.
- Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
- Glucagon-like peptide-1 receptor agonism and end-organ protection.
- Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
- Albumin binding Nanofitins, a new scaffold to extend half-life of biologics - a case study with exenatide peptide.
- Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
- Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.